Trachtenberg J - Search Results

1

Relapse and cure rates of prostate cancer patients after radical prostatectomy and 5 years of follow-up.

Vassilikos EJ, Yu H, Trachtenberg J, Nam RK, Narod SA, Bromberg IL, Diamandis EP. Vassilikos EJ, et al. Among authors: trachtenberg j. Clin Biochem. 2000 Mar;33(2):115-23. doi: 10.1016/s0009-9120(99)00099-5. Clin Biochem. 2000. PMID: 10751589

2

Delay in surgical therapy for clinically localized prostate cancer and biochemical recurrence after radical prostatectomy.

Nam RK, Jewett MA, Krahn MD, Robinette MA, Tsihlias J, Toi A, Ho M, Evans A, Sweet J, Trachtenberg J. Nam RK, et al. Among authors: trachtenberg j. Can J Urol. 2003 Jun;10(3):1891-8. Can J Urol. 2003. PMID: 12892576

3

Assessing individual risk for prostate cancer.

Nam RK, Toi A, Klotz LH, Trachtenberg J, Jewett MA, Appu S, Loblaw DA, Sugar L, Narod SA, Kattan MW. Nam RK, et al. Among authors: trachtenberg j. J Clin Oncol. 2007 Aug 20;25(24):3582-8. doi: 10.1200/JCO.2007.10.6450. J Clin Oncol. 2007. PMID: 17704405

4

Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators.

Nam RK, Kattan MW, Chin JL, Trachtenberg J, Singal R, Rendon R, Klotz LH, Sugar L, Sherman C, Izawa J, Bell D, Stanimirovic A, Venkateswaran V, Diamandis EP, Yu C, Loblaw DA, Narod SA. Nam RK, et al. Among authors: trachtenberg j. J Clin Oncol. 2011 Aug 1;29(22):2959-64. doi: 10.1200/JCO.2010.32.6371. Epub 2011 Jun 20. J Clin Oncol. 2011. PMID: 21690464

5

Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.

Yu H, Diamandis EP, Wong PY, Nam R, Trachtenberg J. Yu H, et al. Among authors: trachtenberg j. J Urol. 1997 Mar;157(3):913-8. J Urol. 1997. PMID: 9072598 Clinical Trial.

6

Prostate specific antigen velocity as a measure of the natural history of prostate cancer: defining a 'rapid riser' subset.

Nam RK, Klotz LH, Jewett MA, Danjoux C, Trachtenberg J. Nam RK, et al. Among authors: trachtenberg j. Br J Urol. 1998 Jan;81(1):100-4. doi: 10.1046/j.1464-410x.1998.00523.x. Br J Urol. 1998. PMID: 9467484

7

Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen.

Nam RK, Diamandis EP, Toi A, Trachtenberg J, Magklara A, Scorilas A, Papnastasiou PA, Jewett MA, Narod SA. Nam RK, et al. Among authors: trachtenberg j. J Clin Oncol. 2000 Mar;18(5):1036-42. doi: 10.1200/JCO.2000.18.5.1036. J Clin Oncol. 2000. PMID: 10694554

8

Significance of the CAG repeat polymorphism of the androgen receptor gene in prostate cancer progression.

Nam RK, Elhaji Y, Krahn MD, Hakimi J, Ho M, Chu W, Sweet J, Trachtenberg J, Jewett MA, Narod SA. Nam RK, et al. Among authors: trachtenberg j. J Urol. 2000 Aug;164(2):567-72. J Urol. 2000. PMID: 10893645

9

HPC2 variants and screen-detected prostate cancer.

Vesprini D, Nam RK, Trachtenberg J, Jewett MA, Tavtigian SV, Emami M, Ho M, Toi A, Narod SA. Vesprini D, et al. Among authors: trachtenberg j. Am J Hum Genet. 2001 Apr;68(4):912-7. doi: 10.1086/319502. Epub 2001 Mar 14. Am J Hum Genet. 2001. PMID: 11254449 Free PMC article.

10

Single nucleotide polymorphism of the human kallikrein-2 gene highly correlates with serum human kallikrein-2 levels and in combination enhances prostate cancer detection.

Nam RK, Zhang WW, Trachtenberg J, Diamandis E, Toi A, Emami M, Ho M, Sweet J, Evans A, Jewett MA, Narod SA. Nam RK, et al. Among authors: trachtenberg j. J Clin Oncol. 2003 Jun 15;21(12):2312-9. doi: 10.1200/JCO.2003.11.007. J Clin Oncol. 2003. PMID: 12805332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

342 results

Search Page

Filters